Yellow fever vaccine: Comparison of the neurovirulence of new 17D-204 Stamaril™ seed lots and RK 168-73 strain

Biologicals

Volumn 41, Issue 4, 2013, Pages 238-246

  Moulin, Jean Claude ^a   Silvano, Jérémy ^b   Barban, Véronique ^a   Riou, Patrice ^a   Allain, Caroline ^a  

^a SANOFI PASTEUR   (France)

^b Centre International de Toxicologie   (France)

Author keywords

17D 204 Stamaril ; Neurovirulence; RK 168 73; Seeds; Vaccine characterization; Yellow fever vaccine

Indexed keywords

AMINO ACID; NONSTRUCTURAL PROTEIN 4B; RK 168 73 VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; YELLOW FEVER VACCINE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; IMMUNOGENICITY; MACACA FASCICULARIS; MALE; MOUSE; NEUROTROPISM; NEUROVIRULENCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PV26 VIRUS STRAIN; RK 168 73 VIRUS STRAIN; S706 VIRUS STRAIN; VACCINE PRODUCTION; VIRUS CULTURE; VIRUS STRAIN; VIRUS TITRATION; VIRUS VIRULENCE;

17D-204 STAMARIL™; CENTRE INTERNATIONAL DE TOXICOLOGIE; CIT; EUR. PH; EUROPEAN PHARMACOPOEIA; FNV; FRENCH NEUROTROPIC VACCINE; IABS; INTERNATIONAL ASSOCIATION FOR BIOLOGICALS SYMPOSIUM; NEUROVIRULENCE; RK 168-73; SEEDS; TECHNICAL REPORT SERIES; TRS; VACCINE CHARACTERIZATION; WHO; WORKING SEED LOT; WORLD HEALTH ORGANIZATION; WSL; YEL-AND; YEL-AVD; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VACCINE-ASSOCIATED NEUROTROPIC DISEASE; YELLOW FEVER VACCINE-ASSOCIATED VISCEROTROPIC DISEASE; YF;

ANIMALS; CERCOPITHECUS AETHIOPS; DNA MUTATIONAL ANALYSIS; FEMALE; MICE; MUTATION; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 84881222335     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2013.04.005     Document Type: Article

References (21)

1. Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines. Proposed replacement of: TRS 872. Annex 2 and Amendment to TRS 872, Annex 2, WHO Technical Report Series No.964 (ECBS 2008); ECBS paper WHO/BS/10.2131 2013, World Health Organization, Geneva.
2. Requirements for yellow fever vaccine (requirements for biological substances no.3 revised 1995). Annex. WHO Expert Committee on Biological Standardization. Forty-sixth report. WHO Technical Report Series No.872 1998, vol. 2. World Health Organization, Geneva.
3. Yellow fever vaccine (live). European Pharmacopoeia 2010, 6.8. Monograph 0537. 6th ed.
4. Yellow fever vaccine (live). European Pharmacopoeia 2012, 7.5. Monograph 0537. 7th ed.
5. Production and testing of the WHO yellow fever primary seed lot 213-77 and reference batch 168-73. Annex. WHO expert committee on biological standardization. Thirty-sixth report. WHO Technical Report Series No 745 1987, vol. 6. World Health Organization, Geneva.
6. Minor P.D. Neurovirulence tests of three 17D yellow fever vaccine strains. Biologicals 2011, 10.1016/j.biologicals.2011.04.001.
7. IABs Scientific Workshop on Neurovirulence Tests for Live Virus Vaccines. Biologicals 2006 Sep, 34(3):233-236. January 31 - February 1, 2005, Geneva.
8. Barban V., Girerd Y., Aguirre M., Gulia S., Pétiard F., Riou P., et al. High stability of yellow fever 17D-204 vaccine: a 12-year retrospective analysis of large-scale production. Vaccine 2007, 25(15):2941-2945.
9. Kärber G. Beitrag zur kollektiven Behandlung pharmakologisher Reihenversuche. Arch Exp Pathol Pharmakol 1931, 162:480-483.
10. Levenbook I.S., Pelleu L.J., Elisberg B.L. The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination. JBiol Stand 1987, 15(4):305-313.
11. Marchevsky R.S., Freire M.S., Coutinho E.S.F., Galler R. Neurovirulence of yellow fever 17DD vaccine virus to thesus monkeys. Virology 2003, 316:55-63.
12. Fox J.P., Penna M.A. Behavior of 17D yellow fever virus in rhesus monkeys. Relation to substrain, dose, and neural or extraneural inoculation. Am J Hyg 1943, 38:152-172.
13. Nathanson N., Goldblatt D., Thind I.S., Davis M., Price W.H. Histological studies on monkey neurovirulence of group B arboviruses. I. Semiquantitative grading scale. Am J Epidemiol 1966, 82:359-381.
14. Miller B.R., Atkins D. Biological characterization of plaque-size variants of yellow fever virus in mosquitoes and mice. Acta Virol 1988, 32:227-234.
15. Stock N.K., Boschetti N., Herzog C., Appelhans M.S., Niedrig M. The phylogeny of yellow fever virus 17D vaccines. Vaccine 2012, 30(6):989-994.
16. Blaney J.E., Manipon G.G., Firestone C.Y., Johnson D.H., Hanson C.T., Murphy B.R., et al. Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. Vaccine 2003, 21(27-30):4317-4327.
17. Tang W.F., Eshita Y., Tadano M., Morita K., Makino Y. Molecular basis for adaptation of a chimeric dengue type-4/Japanese encephalitis virus to Vero cells. Microbiol Immunol 2005, 49(3):285-294.
18. Post P.R., Santos C.N., Carvalho R., Cruz A.C., Rice C.M., Galler R. Heterogeneity in envelope protein sequence and N-linked glycosylation among yellow fever virus vaccine strains. Virology 1992, 188(1):160-167.
19. Ferguson M., Heath A. Collaborative study to assess the suitability of a candidate International Standard for yellow fever vaccine. Biologicals 2004, 32:195-205.
20. Tesh R.B., Guzman H., da Rose A.P., Vasconcelos P.F., Dias L.B., Bunnell J.E., et al. Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. JInfect Dis 2001, 183:1431-1436.
21. Meier K.C., Gardner C.L., Khoretonenko M.V., Klimstra W.B., Ryman K.D. Amouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog 2009, 5:e1000614. [Epub 2009 Oct 9].